Article Text

Download PDFPDF
Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy
  1. Amanda Jane Friend1,2,
  2. Bob Phillips3
  1. 1Paediatrics, Leeds General Infirmary, Leeds, UK
  2. 2School of Medicine, University of Leeds, Leeds, UK
  3. 3Centre for Reviews and Dissemination, University of York Alcuin College, York, UK
  1. Correspondence to Dr Amanda Jane Friend, Paediatrics, Leeds General Infirmary, Leeds LS1 3EX, UK; amanda.friend{at}nhs.net

Statistics from Altmetric.com

Review ofPerkin MR, Bahnson HT, Logan K, et al. Association of early introduction of solids with infant sleep. A secondary analysis of a randomized clinical trial. JAMA Pediatr 2018;172:e180739.

Setting: Tertiary hospital in New Delhi, India.

Patients: Children aged between 5 and 18 years, weighing over 15 kg, who were scheduled to receive their first cycle of highly emetogenic chemotherapy.

Intervention: Olanzapine (0.14 mg/kg orally, once daily, rounded to the nearest 2.5 mg, up to a maximum of 10 mg) during treatment and for 3 days afterwards, in addition to a standard antiemetic regimen (ondansetron, dexamethasone and aprepitant) compared with standard antiemetic alone.

Outcomes: Number of patients with complete response to antiemetics with no vomiting and no severe nausea requiring rescue medication, assessed by hospital investigators during inpatient chemotherapy and reported …

View Full Text

Footnotes

  • Twitter @the_learnaholic, @drbobphillips

  • Contributors AJF wrote the article, incorporating feedback and suggestions from BP.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.